...
cgen-img

Compugen, Common Stock

CGEN

NAQ

$1.52

-$0.01

(-0.65%)

1D
Industry: Life Sciences Tools & Services Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$136.99M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
51
Volume info-icon
This is the total number of shares traded during the most recent trading day.
479.00K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.65
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.35 L
$3.03 H
$1.52

About Compugen, Common Stock

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. more

Industry: Life Sciences Tools & ServicesSector: Health Care

Returns

Time FrameCGENSectorS&P500
1-Week Return-4.4%-0.94%-2.6%
1-Month Return7.8%-5.08%-1.08%
3-Month Return-13.64%-10.62%3.45%
6-Month Return-18.72%-6.18%8.57%
1-Year Return-11.63%1.98%24.3%
3-Year Return-66.67%-0.93%25.58%
5-Year Return-73.79%33.84%84.07%
10-Year Return-82.63%102.52%185.12%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-2.00M6.00M7.50M33.46M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":5.98,"profit":true},{"date":"2021-12-31","value":17.93,"profit":true},{"date":"2022-12-31","value":22.42,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue989.00K60.00K680.00K975.00K2.00M[{"date":"2019-12-31","value":49.35,"profit":true},{"date":"2020-12-31","value":2.99,"profit":true},{"date":"2021-12-31","value":33.93,"profit":true},{"date":"2022-12-31","value":48.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(989.00K)1.94M5.32M6.53M31.45M[{"date":"2019-12-31","value":-3.14,"profit":false},{"date":"2020-12-31","value":6.17,"profit":true},{"date":"2021-12-31","value":16.91,"profit":true},{"date":"2022-12-31","value":20.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin(Infinity%)97.00%88.67%87.00%94.01%[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":91.41,"profit":true},{"date":"2022-12-31","value":89.69,"profit":true},{"date":"2023-12-31","value":96.92,"profit":true}]
Operating Expenses28.88M33.44M40.39M41.90M44.45M[{"date":"2019-12-31","value":64.97,"profit":true},{"date":"2020-12-31","value":75.23,"profit":true},{"date":"2021-12-31","value":90.88,"profit":true},{"date":"2022-12-31","value":94.27,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(28.88M)(31.50M)(35.07M)(35.37M)(12.99M)[{"date":"2019-12-31","value":-2887900000,"profit":false},{"date":"2020-12-31","value":-3149600000,"profit":false},{"date":"2021-12-31","value":-3507400000,"profit":false},{"date":"2022-12-31","value":-3537400000,"profit":false},{"date":"2023-12-31","value":-1299200000,"profit":false}]
Total Non-Operating Income/Expense1.72M3.52M1.74M3.48M6.42M[{"date":"2019-12-31","value":26.85,"profit":true},{"date":"2020-12-31","value":54.86,"profit":true},{"date":"2021-12-31","value":27.14,"profit":true},{"date":"2022-12-31","value":54.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(28.06M)(29.70M)(34.20M)(33.64M)(9.78M)[{"date":"2019-12-31","value":-2805900000,"profit":false},{"date":"2020-12-31","value":-2969800000,"profit":false},{"date":"2021-12-31","value":-3420300000,"profit":false},{"date":"2022-12-31","value":-3363600000,"profit":false},{"date":"2023-12-31","value":-978400000,"profit":false}]
Income Taxes(722.00K)(2.44M)(1.33M)58.00K8.97M[{"date":"2019-12-31","value":-8.05,"profit":false},{"date":"2020-12-31","value":-27.18,"profit":false},{"date":"2021-12-31","value":-14.83,"profit":false},{"date":"2022-12-31","value":0.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(27.34M)(27.26M)(32.87M)(33.69M)(18.75M)[{"date":"2019-12-31","value":-2733700000,"profit":false},{"date":"2020-12-31","value":-2726000000,"profit":false},{"date":"2021-12-31","value":-3287300000,"profit":false},{"date":"2022-12-31","value":-3369400000,"profit":false},{"date":"2023-12-31","value":-1875400000,"profit":false}]
Income From Continuous Operations(27.34M)(29.70M)(34.20M)(33.69M)(18.75M)[{"date":"2019-12-31","value":-2733700000,"profit":false},{"date":"2020-12-31","value":-2969800000,"profit":false},{"date":"2021-12-31","value":-3420300000,"profit":false},{"date":"2022-12-31","value":-3369400000,"profit":false},{"date":"2023-12-31","value":-1875400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(27.34M)(27.26M)(32.87M)(33.69M)(18.75M)[{"date":"2019-12-31","value":-2733700000,"profit":false},{"date":"2020-12-31","value":-2726000000,"profit":false},{"date":"2021-12-31","value":-3287300000,"profit":false},{"date":"2022-12-31","value":-3369400000,"profit":false},{"date":"2023-12-31","value":-1875400000,"profit":false}]
EPS (Diluted)(0.44)(0.37)(0.40)(0.40)(0.22)[{"date":"2019-12-31","value":-44,"profit":false},{"date":"2020-12-31","value":-37,"profit":false},{"date":"2021-12-31","value":-40,"profit":false},{"date":"2022-12-31","value":-40,"profit":false},{"date":"2023-12-31","value":-22,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CGEN
Cash Ratio 4.06
Current Ratio 4.14

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CGEN
ROA (LTM) -3.04%
ROE (LTM) -15.84%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CGEN
Debt Ratio Lower is generally better. Negative is bad. 0.51
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.49

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CGEN
Trailing PE 50.67
Forward PE NM
P/S (TTM) 3.19
P/B 2.25
EV/R 0.46
EV/Ebitda 2.58
PEG NM

FAQs

What is Compugen share price today?

Compugen (CGEN) share price today is $1.52

Can Indians buy Compugen shares?

Yes, Indians can buy shares of Compugen (CGEN) on Vested. To buy Compugen from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CGEN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Compugen be purchased?

Yes, you can purchase fractional shares of Compugen (CGEN) via the Vested app. You can start investing in Compugen (CGEN) with a minimum investment of $1.

How to invest in Compugen shares from India?

You can invest in shares of Compugen (CGEN) via Vested in three simple steps:

  • Click on Sign Up or Invest in CGEN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Compugen shares
What is Compugen 52-week high and low stock price?

The 52-week high price of Compugen (CGEN) is $3.03. The 52-week low price of Compugen (CGEN) is $1.35.

What is Compugen price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Compugen (CGEN) is 51

What is Compugen price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Compugen (CGEN) is 2.25

What is Compugen dividend yield?

The dividend yield of Compugen (CGEN) is 0.00%

What is the Market Cap of Compugen?

The market capitalization of Compugen (CGEN) is $136.99M

What is Compugen’s stock symbol?

The stock symbol (or ticker) of Compugen is CGEN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top